Poolbeg Pharma (POLB) Share Price, News & Analysis

Company Overview

Poolbeg Pharma plc is a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs. Poolbeg comprises a strong and growing portfolio of development assets.

Key Stats

• Today's Range: 3.10 to 3.20
• 50-Day Range: 2.40 to 3.78
• 52-Week Range: 2.25 to 13.80
• Volume: 448,029 shs
• Average Volume: 2.33 million shs
• Market Capitalization: £16.23 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

POLB Stock Analysis - Frequently Asked Questions

How have POLB shares performed this year?

Poolbeg Pharma's stock was trading at GBX 7.10 on January 1st, 2025. Since then, POLB shares have decreased by 55.5% and is now trading at GBX 3.16.

How were Poolbeg Pharma's earnings last quarter?

Poolbeg Pharma PLC (LON:POLB) released its quarterly earnings data on Tuesday, May, 20th. The company reported ($1.16) EPS for the quarter.

How do I buy shares of Poolbeg Pharma?

Shares of POLB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Poolbeg Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Poolbeg Pharma investors own include EQTEC (EQT), Great Western Mining (GWMO), Power Metal Resources (POW), Premier African Minerals (PREM), Rolls-Royce Holdings plc (RR), Alzamend Neuro (ALZN) and Alpine 4 (ALPP).

Company Calendar

• Last Earnings: 5/20/2025
• Today: 7/10/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:POLB
• CIK: N/A
• Web: www.poolbegpharma.com
• Phone: 44 20 7183 1499
• Fax: N/A
• Employees: 12
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): GBX (851.82)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -£4.50 billion
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -32.56%
• Return on Assets: -21.33%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 19.61
• Quick Ratio: 47.96

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: GBX 1.50 per share
• Price / Cash Flow: 2.11
• Book Value: GBX 2,489.80 per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 513,958,333
• Free Float: N/A
• Market Cap: £16.23 million
• Optionable: Not Optionable
• Beta: 2.11